Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old

Each year, around 300,000 Herpes Zoster (HZ) cases are observed in the German population, resulting in costs over €182 million to society. The objective of this study was to estimate the potential public health and economic impact of the new Adjuvanted Recombinant Zoster Vaccine (RZV, Shingrix) in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Oorschot, Desirée, Anastassopoulou, Anastassia, Poulsen Nautrup, Barbara, Varghese, Lijoy, von Krempelhuber, Alfred, Neine, Mohamed, Lorenc, Stéphane, Curran, Desmond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363061/
https://www.ncbi.nlm.nih.gov/pubmed/30130448
http://dx.doi.org/10.1080/21645515.2018.1509645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363061/
https://www.ncbi.nlm.nih.gov/pubmed/30130448
http://dx.doi.org/10.1080/21645515.2018.1509645

Ejemplares similares